Chris Cooley
Stock Analyst at Stephens & Co.
(3.09)
# 1,303
Out of 5,049 analysts
55
Total ratings
71.05%
Success rate
44.18%
Average return
Main Sectors:
Stocks Rated by Chris Cooley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Maintains: Overweight | $39 → $42 | $36.25 | +15.86% | 2 | May 11, 2023 | |
| ALGN Align Technology | Maintains: Overweight | $500 → $375 | $135.67 | +176.41% | 7 | Jul 28, 2022 | |
| COO The Cooper Companies | Maintains: Overweight | $125 → $115 | $69.08 | +66.47% | 9 | Jun 3, 2022 | |
| ALC Alcon | Upgrades: Overweight | $86 → $92 | $74.19 | +24.01% | 4 | May 12, 2022 | |
| PLSE Pulse Biosciences | Maintains: Overweight | $14 → $12 | $16.06 | -25.28% | 2 | Apr 1, 2022 | |
| ANIK Anika Therapeutics | Downgrades: Equal-Weight | n/a | $9.68 | - | 2 | Mar 9, 2022 | |
| ESTA Establishment Labs Holdings | Maintains: Overweight | $88 → $90 | $49.40 | +82.19% | 3 | Nov 10, 2021 | |
| STE STERIS | Maintains: Overweight | $255 → $270 | $241.85 | +11.64% | 5 | Nov 4, 2021 | |
| GKOS Glaukos | Upgrades: Overweight | $60 → $68 | $85.95 | -20.88% | 5 | Nov 3, 2021 | |
| AVNS Avanos Medical | Downgrades: Equal-Weight | $60 → $45 | $11.30 | +298.23% | 2 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $425 → $275 | $124.41 | +121.04% | 5 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $37 | $25.28 | +46.36% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $60 | $61.18 | -1.93% | 3 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $35 | $98.84 | -64.59% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $81 | $320.27 | -74.71% | 2 | Feb 22, 2018 |
Vericel
May 11, 2023
Maintains: Overweight
Price Target: $39 → $42
Current: $36.25
Upside: +15.86%
Align Technology
Jul 28, 2022
Maintains: Overweight
Price Target: $500 → $375
Current: $135.67
Upside: +176.41%
The Cooper Companies
Jun 3, 2022
Maintains: Overweight
Price Target: $125 → $115
Current: $69.08
Upside: +66.47%
Alcon
May 12, 2022
Upgrades: Overweight
Price Target: $86 → $92
Current: $74.19
Upside: +24.01%
Pulse Biosciences
Apr 1, 2022
Maintains: Overweight
Price Target: $14 → $12
Current: $16.06
Upside: -25.28%
Anika Therapeutics
Mar 9, 2022
Downgrades: Equal-Weight
Price Target: n/a
Current: $9.68
Upside: -
Establishment Labs Holdings
Nov 10, 2021
Maintains: Overweight
Price Target: $88 → $90
Current: $49.40
Upside: +82.19%
STERIS
Nov 4, 2021
Maintains: Overweight
Price Target: $255 → $270
Current: $241.85
Upside: +11.64%
Glaukos
Nov 3, 2021
Upgrades: Overweight
Price Target: $60 → $68
Current: $85.95
Upside: -20.88%
Avanos Medical
Aug 4, 2021
Downgrades: Equal-Weight
Price Target: $60 → $45
Current: $11.30
Upside: +298.23%
Mar 23, 2020
Maintains: Overweight
Price Target: $425 → $275
Current: $124.41
Upside: +121.04%
Mar 23, 2020
Maintains: Overweight
Price Target: $56 → $37
Current: $25.28
Upside: +46.36%
Mar 23, 2020
Maintains: Overweight
Price Target: $75 → $60
Current: $61.18
Upside: -1.93%
Mar 23, 2020
Maintains: Overweight
Price Target: $48 → $35
Current: $98.84
Upside: -64.59%
Feb 22, 2018
Maintains: Equal-Weight
Price Target: $60 → $81
Current: $320.27
Upside: -74.71%